I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Change from original
agreement

Terms/Details (Date)


AEterna
Laboratories
Inc.
(Canada;
AELA)

Solvay Pharmaceuticals BV (Belgium

AEterna regained rights to cetrorelix for benign prostate hyperplasia except in Japan; late-stage trials are planned

Solvay is continuing development of the LHRH antagonist in gynecological indications; no payment was made in the restructuring of the January 2004 deal (1/30)

Biomira Inc.
(Canada; BIOM)

Merck KGaA (Germany)

Merck will takes over administrative and financial responsibility for the liposome cancer vaccine L-BLP25

Biomira's co-promotion interest in U.S. sales will be converted to a royalty structure; Biomira retains manufacturing rights, and rights in Canada; milestone terms remain the same (1/26)

Celera
Genomics
(NYSE:CRA)

Abbott Laboratories

They restructured deal focused on development of molecular diagnostics

They will continue working together in most areas in a profit-sharing arrangement but can work individually in certain other areas (1/9)

Cephalon Inc.
(CEPH)

Barr Laboratories Inc.

They settled patent litigation related to Cephalon's Provigil and Actiq products

Barr got nonexclusive rights to market a generic version of Provigil in the U.S. starting in October 2011 and to market a generic version of Actiq starting in December 2006; Cephalon would get royalties (2/1)

Cephalon Inc.
(CEPH)

Mylan
Laboratories
Inc.

They settled a patent
infringement dispute in the
U.S. related to Provigil

Mylan got a nonexclusive, royalty-bearing right to market a generic version of Provigil starting in October 2011 (1/10)

Oscient
Pharmaceuticals
Corp.
(OSCI)

Vicuron Pharmaceuticals Inc. (unit of Pfizer Inc.)

Oscient, which had rights to Ramoplanin in the U.S. and Canada, acquired worldwide rights and assumed full control of the product

Pfizer gets an up-front payment and potential milestone and royalty payments; the drug is nearing Phase III trials for treating Clostridium difficile-associated disease (2/8)

Progenics
Pharmaceuticals
Inc.
(PGNX)

UR Labs Inc.

Progenics acquired a substantial portion of the royalty and milestone rights to methylnaltrexone (MNTX)

Progenics initially licensed rights to the drug from UR Labs in 2001; UR Labs received 686,000 Progenics shares and $2.6M in cash (12/23)

II. TERMINATED AGREEMENTS

Enzon
Pharmaceuticals
Inc.
(ENZN)

Fresenius Biotech GmbH (division of Fresenius AG; Germany)

Enzon returned rights to ATG-Fresenius S, a polyclonal antibody preparation designed for suppressing T lymphocytes

Enzon licensed North American rights to the transplant rejection product in June 2003; Enzon said ending the deal was due to a redirected focus at the company (1/6)

Epigenomics
AG
(Germany;
FSE:ECX)

Roche Diagnostics (Switzerland)

Roche is returning rights to a test for Tamoxifen treatment response and breast cancer molecular classification

Epigenomics plans to develop the test itself; they remain partnered on screening products for colon, prostate and breast cancers (1/30)

Ligand
Pharmaceuticals
Inc.
(PK:LGND)

Organon USA Inc.

They terminated co-promotion deal covering the pain drug Avinza

Ligand regained rights to the product and will continue paying royalties to Organon; they also resolved a dispute concerning prior co-promotion fees (1/17)

NeuroSearch
A/S
(Denmark;
CSE:NEUS)

Boehringer Ingelheim GmbH (Germany)

BI terminated deal covering the development of tesofensine (NS2330)

The move followed unsuccessful Phase II trials in 2005 in Alzheimer's and Parkinson's diseases; NeuroSearch plans continued development with a new partner (1/25)

NitroMed Inc.
(NTMD)

Boston Scientific Corp.

A research program on nitric oxide-enhancing technology came to a close Dec. 31

The technology was being studied with restenosis in balloon angioplasty; NitroMed intends to continue to explore using the technology in medical devices (12/29)

Santarus Inc.
(SNTS)

TAP Pharmaceutical Products Inc.

TAP exercised its right to terminate June 2002 sublicense agreement

TAP had North American rights to use Santarus' immediate- release proton pump inhibitor technology with lansoprazole, a PPI; Santarus now has worldwide rights to the technology (1/9)

SciGen Ltd.
(Australia;
ASX:SIE)

Ferring AG
(Switzerland)

Ferring is terminating deal under which it supplied human growth hormone in Singapore and South Korea

SciGen said it has taken measures to ensure it has adequate supplies for those markets; they are discussing continuation of the collaboration (2/3)


Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets.

No Comments